文献速递心脑血管急症

院前阿片剂量对急性冠脉综合征造影与临床结局的影响

Impact of prehospital opioid dose on angiographic and clinical outcomes in acute coronary syndromes.
PubMed 文献 · Emerg Med J · 2022-04-26
一句话结论院前阿片使用与ACS患者30天MACE无显著相关,但STEMI高剂量阿片组PCI前TIMI 0/1血流比例更高(56% vs 25%,p<0.001)。

该回顾性队列分析链接Ambulance Victoria、Victorian Cardiac Outcomes Registry与Melbourne Interventional Group数据库,纳入2014年1月1日至2018年12月31日期间由急救医疗服务给予阿片并接受PCI的ACS患者,排除心原性休克、院外心脏骤停和溶栓患者,共10531例进入主要分析。调整关键患者和临床因素后,接受阿片与未接受阿片患者的30天MACE无显著差异。在STEMI患者亚组中,高剂量阿片组PCI前TIMI 0或1血流比例显著高于无阿片组(56% vs 25%,p<0.001),调整已知混杂因素后高剂量组预测概率仍更高(33% vs 11%,p<0.001)。作者结论认为阿片使用与30天MACE无关,但STEMI患者使用阿片后PCI前TIMI 0/1血流比例更高,需前瞻性研究验证并探索缺血性胸痛的替代镇痛方案。

要点

  • 接受阿片与未接受阿片的ACS患者30天MACE在调整关键患者和临床因素后无显著差异。
  • STEMI患者中,高剂量阿片组PCI前TIMI 0或1血流比例为56%,无阿片组为25%(p<0.001)。
  • 调整已知混杂因素后,高剂量阿片组预测TIMI 0/1血流概率为33%,无阿片组为11%(p<0.001)。
  • 研究纳入10531例由急救医疗服务给予阿片并接受PCI的ACS患者,排除心原性休克、院外心脏骤停和溶栓患者。
  • 作者认为需前瞻性研究验证上述发现并探索缺血性胸痛的替代镇痛方案。

适用人群与场景

  • 由急救医疗服务给予阿片治疗、诊断为ACS并接受PCI的患者,纳入时间为2014年1月1日至2018年12月31日。
  • 排除心原性休克、院外心脏骤停和接受溶栓治疗的患者。

研究设计与关键结果

  • 研究类型为回顾性队列分析,链接Ambulance Victoria、Victorian Cardiac Outcomes Registry和Melbourne Interventional Group数据库,共10531例患者进入主要分析。
  • 主要终点为接受阿片与未接受阿片患者30天MACE的风险调整比值比,调整关键患者和临床因素后两组无显著差异。
  • STEMI亚组中,高剂量阿片组PCI前TIMI 0或1血流比例为56%,无阿片组为25%(p<0.001)。
  • 调整已知混杂因素后,高剂量阿片组预测TIMI 0/1血流概率为33%,无阿片组为11%(p<0.001)。

证据类型、等级与局限

  • 证据类型:回顾性队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者结论认为阿片使用与30天MACE无关,但STEMI患者使用阿片后PCI前TIMI 0/1血流比例更高。
  • 作者认为需前瞻性研究验证这些发现并探索缺血性胸痛的替代镇痛方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: An adverse interaction whereby opioids impair and delay the gastrointestinal absorption of oral P2Y12 inhibitors has been established, however the clinical significance of this in acute coronary syndrome (ACS) is uncertain. We sought to characterise the relationship between prehospital opioid dose and clinical outcomes in patients with ACS.

METHODS: Patients given opioid treatment by emergency medical services (EMS) with ACS who underwent percutaneous coronary intervention (PCI) between 1 January 2014 and 31 December 2018 were included in this retrospective cohort analysis using data linkage between the Ambulance Victoria, Victorian Cardiac Outcomes Registry and Melbourne Interventional Group databases. Patients with cardiogenic shock, out-of-hospital cardiac arrest and fibrinolysis were excluded. The primary end point was the risk-adjusted odds of 30-day major adverse cardiac events (MACE) between patients who received opioids and those that did not.

RESULTS: 10 531 patients were included in the primary analysis. There was no significant difference in 30-day MACE between patients receiving opioids and those who did not after adjusting for key patient and clinical factors. Among patients with ST-elevation myocardial infarction (STEMI), there were significantly more patients with thrombolysis in myocardial infarction (TIMI) 0 or 1 flow pre-PCI in a subset of patients with high opioid dose versus no opioids (56% vs 25%, p<0.001). This remained significant after adjusting for known confounders with a higher predicted probability of TIMI 0/1 flow in the high versus no opioid groups (33% vs 11%, p<0.001).

CONCLUSIONS: Opioid use was not associated with 30-day MACE. There were higher rates of TIMI 0/1 flow pre-PCI in patients with STEMI prescribed opioids. Future prospective research is required to verify these findings and investigate alternative analgesia for ischaemic chest pain.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Fernando H, Nehme Z, Dinh D, et al. Impact of prehospital opioid dose on angiographic and clinical outcomes in acute coronary syndromes. Emerg Med J. 2022. PMID: 35473753. doi:10.1136/emermed-2021-211519

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。